Navigation Links
ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease
Date:2/26/2009

will be evaluated in comparison to placebo. Ambulatory patients suffering from mild to moderate Alzheimer's disease are randomized and receive oral treatment, twice a day, of either 40 or 80 mg of EHT 0202, or placebo over a three-month period. The study design will also allow for the collection of preliminary data related to many clinical efficacy parameters of EHT 0202, notably including a battery of cognitive assessments (ADAS-Cog, NTB, MMSE) but also assessment of patients' daily living activities, global assessment and behaviour.

Study results will be available in Q4 2009.

About EHT 0202

EHT 0202 has a novel mechanism of action when compared to existing Alzheimer's disease therapeutics: it stimulates the alpha-secretase pathway, thus enhancing the production of the procognitive and neuroprotective sAPPalpha fragment of APP (Amyloid Precursor Protein). The stimulation of the alpha-secretase pathway being to the detriment of Abeta amyloid peptide production, EHT 0202 potentially reduces toxic Abeta plaque formation [1].

Phase I studies demonstrated good tolerability of EHT 0202 in both young and aged healthy volunteers; importantly, no sedation or emesis were observed clinically.

Preclinical studies have shown that EHT 0202 protects cortical neurons against Abeta42-induced stress and that this neuroprotection is associated with sAPPalpha induction. EHT 0202 has also demonstrated pro-cognitive properties in several animal models: age-related memory impairment and scopolamine-induced amnesia [2].

About Alzheimer's disease

Alzheimer's disease is the most frequent cause of dementia in the aging population. The World Health Organization estimated in 2001 that 18 million people around the world were suffering from Alzheimer's disease and that this figure could nearly double by 2025 to 34 million [3].

About ExonHit Therapeutics


'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
2. ExonHits EHT 0202 Counters Scopolamines Detrimental Effects on Cognition in Humans
3. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
4. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
5. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
6. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
7. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
8. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
9. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
10. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
11. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new ... targeting guide with accompanying instrumentation to place and insert ... to the soft tissue (e.g. ligament) repair or reconstruction ... repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
(Date:1/14/2014)... VALHALLA, N.Y. , Jan. 14, 2014   Oligomerix, Inc. ... disease modifying therapeutics for Alzheimer,s disease (AD) and related ... headquarters to Valhalla, NY as ... additional laboratory space at New York Medical College. ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Calif., Dec. 7, 2010 Anthera Pharmaceuticals, Inc. (Nasdaq: ... to treat serious diseases associated with inflammation, today announced ... 2010 European Society Pediatric Research Award at the Third ... in Copenhagen, Denmark where Dr. Daniele De Luca, MD, ...
... 2010 Alder Biopharmaceuticals Inc. today announced that data ... antibody therapeutic that targets interleukin-6 (IL-6) demonstrate a reversal ... cancer (NSCLC). After 12 weeks of treatment ... received ALD518 experienced hemoglobin level increases from less than ...
Cached Medicine Technology:Varespladib Receives 2010 European Society Pediatric Research Award 2Varespladib Receives 2010 European Society Pediatric Research Award 3Data from Phase 2 Study of Alder Biopharmaceuticals' Anti-IL-6 Antibody Therapeutic, ALD518, Demonstrate Reversal of Anemia in Patients with Advanced Non-Small Cell Lung Cancer 2
(Date:7/10/2014)... For decades, health-conscious people around the globe have ... figuring this was one of the paths to good ... clinical trials of antioxidant supplements have repeatedly dashed the ... their cancer risk. Virtually all such trials have ... In fact, in several trials antioxidant supplementation has been ...
(Date:7/10/2014)... new drug could prove useful in treating small cell lung ... Scientists from the Cancer Research UK Manchester Institute, based at ... Research Centre, teamed up with experts at AstraZeneca, as part ... known as AZD3965 - on small cell lung cancer ... Cancer Research , also helps identify which patients are most ...
(Date:7/9/2014)... acute episodes of low back pain are not linked ... wind direction and precipitation. Findings published in Arthritis ... College of Rheumatology (ACR), indicate that the risk of ... or wind gusts, but was not clinically significant. ... everyone experiences low back pain at some point in ...
(Date:7/9/2014)... Wakulich was told she had an aneurysm, she figured an ... , "I was devastated," said Wakulich, who is 56 years ... was a serious diagnosis. Then I met Dr. Bernard Bendok ... less invasive procedure. It was something I didn,t even know ... multi-center U.S. clinical trial to evaluate the safety and effectiveness ...
(Date:7/9/2014)... of stromal support cells and immune cells and ... in the development of diseases could open new ... was the conclusion of a review article by scientists ... Nature . , Prof. Peter Carmeliet: "Consider the ... of cancer cells has been examined in minute detail ...
Breaking Medicine News(10 mins):Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Low back pain? Don't blame the weather 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Wake-up call for more research into cell metabolism 2
... researchers have found that even before infants begin to speak, ... infants, words influence performance in a cognitive task in a ... sounds, including musical tones. The research by ... department in the Weinberg College of Arts and Sciences, will ...
... ... three drive autoloader with a compact body suitable for any office space. , ... (Vocus) March 25, 2010 -- Vinpower Digital announced today the ... autoloader duplication system. This unit offers many of the options and benefits expected ...
... ... purchased key technology assets from Regenerative Medicine Assets Limited (formerly Intercytex Group plc), a ... ... Institute Inc. (ARI) announced it purchased key technology assets from Regenerative Medicine Assets Limited ...
... ... technology can transform the way utilities can deliver power to customers," said President & ... ... have discovered that smart grid will change every aspect of their business -- from ...
... UCSF researchers have shown that delivering HIV prevention services to ... their sexual risk behaviors. The findings are available now ... Behavior " and are scheduled for publication in an upcoming ... reductions in sexual risk took place when the prevention interventions ...
... in normal-weight women, suggesting it protects against obesity , WEDNESDAY, ... a well-known marker of inflammation may help determine how much ... was not present in obese individuals, according to the research, ... March 25 issue of the New England Journal of ...
Cached Medicine News:Health News:Talk to your babies 2Health News:Vinpower Digital Introduces the 3 Drive CUBE Autoloader Series 2Health News:Aderans Research Acquires Intercytex Assets 2Health News:PERI Software Solutions CEO Sarav Periasamy to Attend DistribuTECH Conference and Exhibition in Tampa, FL 2Health News:PERI Software Solutions CEO Sarav Periasamy to Attend DistribuTECH Conference and Exhibition in Tampa, FL 3Health News:UCSF study finds clinic-based HIV prevention is effective in reducing risk behaviors 2Health News:Inflammation Molecule May Determine Fat Levels 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: